Introduction
Annual influenza epidemics are responsible for the deaths of 250000 to 500000 people worldwide and cause illness in 5 to 15% of the total population each year [1] . The total direct and indirect costs associated with influenza in the USA are roughly $10 billion [2] , and the economic cost of an influenza pandemic is estimated to be between $71-167 billion [3] in the USA alone. Vaccination is the primary method employed to prevent infection by influenza and its associated complications. Antigenic change, combined with the high transmission rate of influenza strains, means that the vaccine must be redesigned annually, currently based upon phylogenetic, experimental, and epidemiological analysis.
The effectiveness of the annual influenza vaccine varies from year to year due to changes in the identity of the circulating influenza strains. Typically, three strains are included in the annual vaccine, with these three strains chosen to be as similar as possible to those projected to be the most prominent circulating strains in the upcoming influenza season. Currently, the vaccine contains H3N2 and H1N1 influenza A components and an influenza B component. Since the mutation rate of the influenza virus is rather high, vaccine efficacies are rarely 100%, and are more typically 30 -60%, against influenzalike illness. As significant as the estimated worldwide mortality is, it rises by another factor of 160% [4] to 260% [5] if influenza-induced complications to patients with other conditions are included, and the influenza vaccine on average significantly reduces such excess mortality [6] . Vaccine efficacy can even be negative, however, due to original antigenic sin [7, 8, 9] , the tendency for antibodies produced in response to exposure to influenza vaccine antigens to suppress the creation of new, different antibodies in response to exposure to new versions of the influenza virus. The efficacy of the annual influenza vaccine, and whether original antigenic sin may occur, depends sensitively on how similar the vaccine and circulating viral strains are. Current state of the art measures of antigenic distance are based on ferret antisera hemagglutinin inhibition assays [10, 11, 12] , and these distances are assumed to correlate well with vaccine efficacies in humans. However, to our knowledge no such good correlation has ever been shown for an experimental or theoretical measure of antigenic distance. In addition to its annual value, a reliable measure of antigenic distance would provide valuable extra time if preparation and rush production of a modified vaccine is necessary to stem the spread of a newly emerged influenza strain [13] . We here provide a quantitative definition of the difference between dominant epitope regions in the vaccine and circulating strain and show that this definition of antigenic distance correlates well with human influenza vaccine efficacy over the last 35 years.
Methods
Our theory models the response of an immune system not subject to immunosenescence. Therefore, we limited consideration to experimental studies of vaccine efficacy for 18 to 64 year old subjects in all years since sequencing began, when the H3N2 subtype of influenza A was the predominant virus, and where epidemiological data on vaccine efficacy exists. We focus on the H3N2 strain because it is the most common strain and is responsible for significant morbidity and mortality and due to the abundance of available crystallographic, genetic, and epidemiological data. Our approach, however, is general. As is customary, we restrict attention to the hemagglutinin protein, against which neutralizing antibodies are generated [14] . Shown in figure 1 is the hemagglutinin protein for the A/Fujian/411/2002 strain with the epitope regions highlighted.
Our theory of the immune response to vaccination and disease uses the generalized NK model [9] to calculate affinity constant values for the immune response to an antigen following vaccination. In this theory, the natural order parameter to distinguish between the vaccine strain and the circulating strain is the fraction of amino acids that differ in the dominant epitope region.
The model considers the diversity of an individual's antibody repertoire and includes interactions within the antibody and between the antibody and the antigen. Here, the binding constant is determined as K = exp(a − bU), where a = −18.56 and b = 1.67 are found from a comparison of the dynamics of the model with experiment [9] , and U is the energy function for an antibody [9] .
To apply the theory to a candidate vaccine and circulating strain, the sequences and identity of the dominant epitope must be known. The sequences and identities of the vaccine and circulating strains for each year were taken from Ref. [15] . The definition of the five epitopes, or surface regions that are recognized by human antibodies, in the H3N2 hemagglutinin protein were also taken from Ref. [15] . The dominant epitope, or the epitope that induces the most significant immune response, for a particular circulating strain in a particular year was taken as that which had the largest fractional change in amino acid sequence relative to the vaccine strain [16, 17, 18, 19] . We use as our definition of antigenic distance p epitope , where p epitope = number of amino acid differences in the dominant epitope total number of amino acids in the dominant epitope .
The difference between the vaccine strain and the circulating strain is defined in the model by p epitope , eq. 1. The vaccine efficacy, E, was assumed to correlate with the binding constant as
where the constant α is chosen so that a perfect match between the vaccine and circulating strain leads to 47% vaccine efficacy (which matches historical data, see table 1), K primary is the binding constant for the primary immune response, and K secondary is the binding constant for the secondary immune response following vaccination. The theory is entirely predictive, with no fitted parameters save for the determined constant α. For example, the point at which the vaccine efficacy becomes negative is independent of the value of α.
Results
Shown in figure 2 and 
where u is the influenza-like illness rate of unvaccinated individuals, and v is the influenza-like illness rate of vaccinated individuals. While the epidemiological estimates of u and v contain statistical noise, these are the best estimates available of vaccine efficacy in humans. The statistical mechanical model captures the essential physics of the immune response to influenza vaccination and demonstrates the value of using p epitope to define the degree of antigenic drift. Consideration of antigenic drift of the dominant epitope follows from immunoassays and crystallographic data that show only the epitope regions are significantly involved in immune recognition [35] . When the antigenic drift, p epitope , in the dominant epitope is greater than 0.19, according to historical records, or 0.22, according to theory, the vaccine efficacy becomes negative (see figure 2 ). This regime is to be avoided. For example, in the 1997/1998 northern hemisphere influenza season, when the Sydney/5/97 strain became widespread, p epitope = 0.238, and the vaccine efficacy was -18 % [29] . The only data point that falls significantly off the theory is that for the 1989/1990 epidemic [36] , in which it is likely that multiple circulating strains were present, including influenza B strains [37, 24] .
When the vaccine efficacy is compared to the sequence difference of the entire hemagglutinin protein, p sequence = number of amino acid differences in the sequence total number of amino acids in the sequence ,
one current measure of antigenic drift used to construct phylogenetic relationships between circulating strains for the WHO February report [38] , the correlation is far less apparent. These data are shown in figure 3 and table 1.
Since much of the protein is inaccessible to antibodies or simply not recognized by human antibodies, drift in much of the protein sequence is not correlated with vaccine efficacy.
When the vaccine efficacy is compared to the antigenic distance derived from ferret antisera [11, 12] , the dominant current measure of antigenic drift used to confirm phylogenetic strain analysis [38] , the correlation is again less apparent.
These data are shown in figure 4 and table 1. It appears that the ferret antisera experiments capture no more information than does the analysis with p sequence .
A ferret-derived antigenic distance of zero does not always guarantee that the two strains are identical. For example, for the 1996/1997 vaccine strain of A/Nanchang/933/95 and circulating strain of A/Wuhan/359/95, the ferretderived antigenic distance was zero, whereas, p epitope = 0.095, and the vaccine efficacy was 27% in the northern hemisphere [31] and 11% the next year in the southern hemisphere [30] . These values are much lower than the average for a perfect match between vaccine and circulating strains, which is 47%.
Discussion
Vaccine design is done under considerable time pressure. At present, the WHO and national health agencies in the northern hemisphere determine the components of the annual flu vaccine between February and April. The vaccine is then produced by growing virus in hen's eggs, and it is distributed in September after regulatory tests in mid-July [39] . Data collection relating to the effectiveness of the vaccine can begin in October, and by January a very good measure of the season's vaccine has been obtained. The availability of high-growth reassortments from egg-cultured strains imposes additional constraints on the choice of possible vaccine strains. Given the constraints imposed by the biology and manufacturing process, one wishes to choose the strain that provides the best possible match to the anticipated circulating strain for the following season.
We believe that the antigenic distance between strains would profitably be defined by world health professionals as p epitope (figure 2), rather than as se- We suggest that antigenic drift in the dominant epitope, p epitope , will provide a prediction measure of efficacy for such vaccines. This quantitative measure of efficacy may then be used to determine the frequency and nature of vaccine redesign that is necessary.
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Appendix: The Generalized NK Model
Our theory of the immune response to vaccination and disease uses the generalized NK model [9] to calculate affinity constant values for the immune response to an antigen following vaccination. In this theory, the natural order parameter to distinguish between the vaccine strain and the circulating strain is the fraction of amino acids that differ in the dominant epitope region, p epitope .
The model considers the diversity of an individual's antibody repertoire and includes interactions within the antibody and between the antibody and the antigen. Here, the binding constant is determined as K = exp(a−b U ), where a = −18.56 and b = 1.67 are found from a comparison of the dynamics of the model with experiment [9] and U is the energy function for an antibody and is defined as
The parameters within the generalized block NK model represent the number of secondary structures and the total size of the variable region [9] . We have L = 5 different subdomain energy functions of the NK form
where a j is the amino acid type of the jth amino acid in the subdomain, and α i is the type of the ith subdomain. As in previous studies, we consider the case where the range of the interactions within a subdomain is specified by K = 4 and there are N = 10 amino acids in each subdomain [45] . Here σ α i is a quenched Gaussian random number with zero mean and a variance of unity, and it is different for each value of its argument for each of the L subdomain types, α i . The interaction energy between secondary subdomain structures is given by
Here M = 10 is the number of antibody secondary structural subdomains. We consider D = 6 interactions between secondary structures [45] . The zero-mean, unit-variance Gaussian σ 
where the zero-mean, unit-variance Gaussian σ i and the contributing amino acid, i, are chosen at random.
To model the immune system dynamics, we use 30 rounds of point muta- uses only naive cells [9] . [12] , are determined from the literature [11, 38, 46, 48, 49, 47, 51, 50] . Where more than one antisera assay has been performed, the calculated distances are averaged. [12] , derived from ferret antisera experiments. Experimental data were collected from a variety of sources [11, 38, 46, 48, 49, 47, 51, 50] .
Results were averaged when multiple hemagglutination inhibition (HI) studies had been performed for a given year. These HI binding assays measure the ability of ferret antisera to block the agglutination of red blood cells by influenza viruses.
Also shown are linear least squares fits to the d 1 (long dashed, R 2 = 0.54) and 
